Details of the Drug Combinations

General Information of This Drug (ID: DMH7GN8)

Drug Name

Ramosetron DMH7GN8

Synonyms

132036-88-5; UNII-7ZRO0SC54Y; Ramosetron [INN]; 7ZRO0SC54Y; CHEMBL1643895; Ramosetron (INN); (1-methylindol-3-yl)-[(5R)-4,5,6,7-tetrahydro-3H-benzimidazol-5-yl]methanone; Nor-YM 060; SCHEMBL16701; GTPL2301; DTXSID0043842; NTHPAPBPFQJABD-LLVKDONJSA-N; MolPort-019-991-383; CHEBI:135156; ZINC5116719; AC1L3355; BDBM50334454; 8235AH; AKOS015896003; SB19072; DB09290; SC-92398; AJ-53160; LS-187182; TL8000762; R-146; FT-0651831; D08466; A806353; (-)-(R)-1-Methylindol-3-yl-4,5,6,7-tetrahydro-5-benzimidazolyl ketone; Nasea (TN); YM060

Indication

Disease Entry	ICD 11	Status	REF
Diarrhea-predominant irritable bowel syndrome	DD91.01	Approved	[1]
Nausea and vomiting	MD90	Approved	[2]
Irritable bowel syndrome	DD91.0	Phase 4	[3]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Aprepitant + Ramosetron	DCPF48D	Aprepitant	Postoperative Nausea and Vomiting	[4]
Naloxone + Ramosetron	DC23SSD	Naloxone	Postoperative Nausea and Vomiting	[5]
Ramosetron + Morphine	DCV66DD	Morphine	Postoperative Nausea and Vomiting	[5]
------------------------------------------------------------------------------------

References

1	Current and emerging pharmacological approaches for treating diarrhea-predominant irritable bowel syndrome. Expert Opin Pharmacother. 2020 Jan;21(1):63-71.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2301).
3	ClinicalTrials.gov (NCT01225237) A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients. U.S. National Institutes of Health.
4	ClinicalTrials.gov (NCT02597907) Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant
5	ClinicalTrials.gov (NCT02416115) Anti Emetic Efficacy of Combination of Ramosetron and Premixture of Naloxone With Patient-controlled Analgesia